about
MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsisNidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancerModulation of mismatch repair and genomic stability by miR-155MicroRNA gene expression deregulation in human breast cancerMicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocalityGenome wide identification of recessive cancer genes by combinatorial mutation analysis.Reprogramming of miRNA networks in cancer and leukemia.MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.Micromarkers: miRNAs in cancer diagnosis and prognosis.NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15).MicroRNAs dysregulation in human malignant pleural mesothelioma.Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.Mutated beta-catenin evades a microRNA-dependent regulatory loop.MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma.p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2.MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells.MicroRNA profiling for the identification of cancers with unknown primary tissue-of-originmiR-181b is a biomarker of disease progression in chronic lymphocytic leukemiamRNA/microRNA gene expression profile in microsatellite unstable colorectal cancerA novel miR-371a-5p-mediated pathway, leading to BAG3 upregulation in cardiomyocytes in response to epinephrine, is lost in Takotsubo cardiomyopathymiR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling.Karyotype-specific microRNA signature in chronic lymphocytic leukemia.MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene.Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.Oncogenic role of miR-483-3p at the IGF2/483 locus.Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma.Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.Anticancer activity of an adenoviral vector expressing short hairpin RNA against BK virus T-ag.Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib.The Glucose-Regulated MiR-483-3p Influences Key Signaling Pathways in Cancer.The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profileMicroRNAs in Autoimmunity and Hematological MalignanciesA Developmental Perspective on Paragangliar TumorigenesisChronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosisCryptic insertion producing two NUP98/NSD1 chimeric transcripts in adult refractory anemia with an excess of blasts
P50
Q21091178-C39ED965-4825-4C87-9464-184253D4E12FQ21245734-2253D49E-B965-4A89-ADC1-D7CEA971EA32Q24612859-8F962389-9957-4A07-9D4A-A6AF1A15DFAAQ27860690-2A05E4E6-14EE-44DC-A690-A44CA3585D9AQ28115464-21DF43B3-08C1-4B31-B8CE-97513AEE1863Q33375045-D3D7DBDF-C9E9-47FA-BECC-FAEDAD77D3B9Q33812540-AF39EEE3-68E0-420C-B708-BBBC48177D44Q33942272-CB27C424-321C-4247-AB0F-1A161474E78DQ34108602-039790B3-399D-4A9C-85EF-A2796161DCB2Q34126338-7A3650A0-C668-4C8C-8651-091348731354Q34167369-74A9888C-4D67-4E78-9C4E-017D4A658F41Q34368733-0F0F210C-692F-4200-8E20-4F5A0852A423Q34647028-657D179C-0672-4993-A3ED-5F3E749C7D9EQ34720637-41CD088B-D53F-4D65-A917-6254E03C0566Q34784133-4E3E6832-E771-4408-8D5D-65AE8580C76BQ34973748-9B7F4AB3-B688-4E2B-901E-6B00958C9DBDQ34991081-CF44B8C0-B654-4737-A304-DA4C3C9D884BQ35001206-2021CD11-13E7-4766-A0B3-6F32F7102134Q35075757-25BFF9A3-F158-4E2F-9DFF-78D4A9894637Q35220412-B0CBAC59-97E7-4008-9891-01CB0144BAB7Q36103305-F2986D5B-6AF8-426E-891B-F1B8C5EE5105Q36246459-0ABC57DD-C4A9-471D-BD5B-689A07EAF6C7Q36293886-8F03E55B-AFCA-437E-BA08-B0E269BA46DDQ37213634-3BE0BF18-DB88-4E4F-8E2A-32551AC41B27Q37412319-E7109EDD-CB78-4502-A837-5021982E3E14Q37715770-CE00DDFF-8086-4211-B75E-0F1ED061C9E1Q38316664-CA60C836-1BAA-4685-BC90-E314FA36EB9BQ39004167-96718D12-3C07-4B33-80CB-E2282F84E685Q39044964-12584BB2-14CE-4C87-AE42-887B92547E68Q39715206-A11FF9E7-DB9A-4677-B8A2-1815C43B351EQ39817084-498212AD-EC69-4718-A36B-DD0EEA37E7B7Q41146935-4CB563AF-C158-44AD-A8EC-2C50D021D670Q45408352-D807960E-7EB7-4B25-BA23-FE33B398AF68Q47228308-5A1F2135-ED2C-4051-AD1F-0DC2647C5EE6Q55483353-801C3FBB-6407-4106-869E-82994E49CB27Q56097627-973E83DF-0377-4021-947B-B40FDCDA8141Q57471217-48F0B415-4345-4F55-AB40-8D0DB1125DF9Q64099571-1AD21531-CDAF-4755-BCFD-0BBB4FF1C143Q75231224-32355EB9-C54F-4D95-93BC-087625DD4FDFQ80594737-FC2107F5-A1D3-429F-B1A5-0C6262590E09
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Angelo Veronese
@ast
Angelo Veronese
@en
Angelo Veronese
@es
Angelo Veronese
@nl
Angelo Veronese
@sl
type
label
Angelo Veronese
@ast
Angelo Veronese
@en
Angelo Veronese
@es
Angelo Veronese
@nl
Angelo Veronese
@sl
prefLabel
Angelo Veronese
@ast
Angelo Veronese
@en
Angelo Veronese
@es
Angelo Veronese
@nl
Angelo Veronese
@sl
P106
P1153
35231283300
P21
P31
P496
0000-0002-1451-1392